Sabalalisa i-B-cell lymphoma (DBCL) enkulu, i-NOS, uhlobo oluncane lwe-GCB, uhlelo oluyisisekelo lwe-nervous lymphoma-01

NgoZibandlela wezi-2019, uMnu. Wang, uthisha waseNyakatho-mpumalanga yeChina, waqala ukuphathwa yikhanda. Ngomhla ziyi-19 kuZibandlela, 2019, izivivinyo zokuxilonga zembule lokhu okulandelayo: I-PET-CT ibonise ithunzi lokuminyana elinokwenyuka kakhulu kwe-FDG metabolism engxenyeni engaphambili yesokunxele kanye nendawo yedolo le-corpus callosum (cishe u-3.4 * 1.9 cm, SUVmax=34.4). I-Biopsy kanye ne-immunohistochemistry kuqinisekisile ukusakazeka kwe-B-cell lymphoma enkulu (DLBCL, NOS, GCB subtype), ene-immunophenotype ekhombisa i-Ki67(50%+), CD19(+), CD20(+), PAX5(+), CD79(+), MUM1(+), BCL(+), CD10(-/+), CD2(minor+). Ukuhlaziywa koketshezi lwe-cerebrospinal kwembule amaseli e-lymphoid angama-6% angavuthiwe anokushintshashintsha kwe-morphological. Ukuxilongwa kwakuyi-primary central central nervous system lymphoma (DBCL, GCB subtype).

Ngemva kokucwaninga ngezinketho zokwelapha ku-inthanethi, uMnu. Wang wafunda ngamakhono e-Lu Dao Pei Hospital's immunotherapy futhi wafuna ulwazi lwabo ngokushesha. Ngemva kokuhlolwa okuphelele komzimba nokuhlaziywa okucophelela kwethimba lochwepheshe besibhedlela, kwanqunywa ukuthi uMnu. Wang abambe iqhaza ocwaningweni lomtholampilo lokwelashwa kwe-CART, ikakhulukazi esebenzisa amaseli e-CD19 CART. Uthole ukufakwa kweseli ye-CD19 CAR-T ezenzakalelayo ngo-April 24, 2023. Ngomhla zingama-30 kuJulayi, 2023, wahlolelwa ukuthi uthole ukuxolelwa okuphelele (CR) futhi usebuyele empilweni evamile.